Anixa Biosciences (ANIX) stock price, revenue, and financials

Anixa Biosciences market cap is $71 m, and annual revenue was $250 k in FY 2019
View Company

$71 M

ANIX Mkt cap, 13-Feb-2020

$250 K

Anixa Biosciences Revenue FY, 2019
Anixa Biosciences Net income (FY, 2019)-11.8 M
Anixa Biosciences EBIT (FY, 2019)-11.9 M
Anixa Biosciences Cash, 31-Oct-20193.5 M
Anixa Biosciences EV69.5 M

Anixa Biosciences Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.0m947.1k388.9k3.7m9.3m300.0k362.5k1.1m250.0k

Revenue growth, %

152%

Cost of goods sold

34.1k3.9k

Gross profit

969.1k943.2k

Gross profit Margin, %

97%100%

R&D expense

3.1m2.2m1.6m1.6m6.8m5.5m

General and administrative expense

2.9m2.9m8.0m6.4m6.2m2.7m4.4m6.9m5.7m

Operating expense total

6.0m5.1m8.0m6.4m6.2m4.3m6.0m13.7m11.1m

Depreciation and amortization

314.5k325.3k325.3k325.3k325.3k418.8k

EBIT

(5.0m)(4.1m)(7.9m)(5.0m)(944.8k)(4.5m)(6.1m)(14.3m)(11.9m)

EBIT margin, %

(501%)(437%)(2036%)(138%)(10%)(1503%)(1676%)(1284%)(4756%)

Interest expense

7.7k

Interest income

2.5k3.5k125.08.6k17.6k12.5k19.4k46.0k71.4k

Pre tax profit

(6.8m)(4.3m)(10.1m)(9.6m)(1.4m)(5.0m)(5.0m)(14.2m)(11.8m)

Income tax expense

600.0k

Net Income

(7.4m)(4.3m)(10.1m)(9.6m)(1.4m)(5.0m)(7.0m)(14.0m)(11.8m)

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q3, 2019

Revenue

450.4k449.2k248.1k249.5k2.1k1.2m9.1m25.0k95.0k100.0k362.5k750.0k362.5k

Cost of goods sold

3.6k737.0497.0714.027.1k

Gross profit

446.7k448.5k247.6k248.8k(24.9k)

Gross profit Margin, %

99%100%100%100%(1171%)

R&D expense

879.6k649.7k604.2k458.4k451.6k431.1k363.0k777.9k660.2k2.9m2.2m1.1m

General and administrative expense

774.7k686.0k521.6k433.7k2.0m1.9m2.2m1.9m1.8m1.1m1.8m2.0m1.4m1.3m1.1m923.3k859.9k699.3k1.5m990.0k908.8k2.7m2.1m1.1m

Operating expense total

1.7m1.3m1.1m892.1k2.0m1.9m2.2m1.9m1.8m1.1m1.8m2.0m1.4m1.3m1.1m923.3k1.3m1.1m1.9m1.8m1.6m5.6m4.3m2.1m

Depreciation and amortization

81.4k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k251.3k41.9k

EBIT

(1.2m)(887.3k)(878.2k)(643.3k)(2.1m)(1.9m)(2.2m)(2.0m)(1.4m)(159.6k)3.9m(2.1m)(1.5m)(1.5m)(1.1m)(974.9k)(1.4m)(1.2m)(1.7m)(1.9m)(1.4m)(5.6m)(5.0m)(2.2m)

EBIT margin, %

(268%)(198%)(354%)(258%)(97315%)(13%)42%(8533%)(1569%)(975%)(477%)(187%)(1546%)

Interest expense

22.2k835.5k125.0k

Interest income

653.01.2k1.1k773.07.030.076.01.4k1.9k1.5k4.7k5.2k4.5k3.3k3.5k3.5k999.0626.08.2k9.1k8.4k12.2k17.1k18.4k

Pre tax profit

(1.2m)(886.1k)(877.1k)(629.1k)(2.1m)(2.5m)(2.6m)(3.6m)(3.2m)411.0k3.8m(2.2m)(1.6m)(1.6m)(1.3m)(1.1m)(1.6m)160.5k(1.8m)(1.9m)(1.4m)(5.6m)(5.0m)(2.2m)

Income tax expense

600.0k

Net Income

(1.8m)(886.1k)(877.1k)(629.1k)(2.1m)(2.5m)(2.6m)(3.6m)(3.2m)411.0k3.8m(2.2m)(1.6m)(1.6m)(1.3m)(1.1m)(3.6m)160.5k(1.8m)(1.8m)(1.4m)(5.5m)(5.0m)(2.2m)

Anixa Biosciences Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

774.0k339.7k898.2k3.4m4.4m2.5m3.3m3.1m3.5m

Accounts Receivable

7.0k175.0k400.0k66.5k

Prepaid Expenses

97.2k82.3k160.6k60.6k126.5k162.1k174.6k482.5k185.0k

Current Assets

3.1m922.0k1.2m6.3m6.9m3.4m7.0m5.5m6.1m

PP&E

15.9k10.3k8.4k11.9k43.5k156.6k52.7k72.7k200.6k

Total Assets

8.6m5.7m5.4m9.1m9.3m5.6m8.8m6.4m6.3m

Accounts Payable

374.7k304.5k527.2k540.2k374.7k373.2k480.3k582.0k585.8k

Short-term debt

314.5k639.7k1.4m1.3m1.6m2.0m

Current Liabilities

2.1m1.8m3.2m1.8m593.8k468.8k889.5k1.3m1.5m

Long-term debt

32.3k548.6k

Total Debt

32.3k548.6k314.5k639.7k1.4m1.3m1.6m2.0m

Total Liabilities

5.0m4.3m4.6m889.5k

Common Stock

1.8m1.8m2.1m2.2m87.2k87.5k166.0k189.1k203.3k

Preferred Stock

350.0k14.0k14.0k

Additional Paid-in Capital

125.1m127.7m134.8m146.2m151.1m152.1m163.9m175.4m186.8m

Retained Earnings

(120.8m)(125.1m)(135.2m)(144.8m)(146.1m)(151.2m)(156.2m)(170.2m)(181.8m)

Total Equity

1.1m(1.2m)(3.3m)4.0m5.1m987.5k7.9m5.2m4.8m

Financial Leverage

8.2 x-4.7 x-1.6 x2.3 x1.8 x5.7 x1.1 x1.2 x1.3 x

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

551.4k463.0k130.7k101.5k1.7m1.3m982.0k776.1k617.7k3.7m7.8m6.1m5.2m4.0m2.6m2.0m1.4m2.9m1.8m2.8m4.2m2.6m4.2m3.8m4.4m

Accounts Receivable

828.4k133.3k45.0k221.0k797.0k1.1k

Prepaid Expenses

61.0k97.2k107.5k93.3k67.0k52.1k47.3k141.3k134.2k100.6k66.5k42.5k193.6k55.8k39.0k56.4k68.6k64.6k140.3k278.5k298.2k378.5k333.7k124.3k129.6k

Inventories

33.4k

Current Assets

3.6m2.6m1.8m1.1m1.8m1.3m1.0m3.4m3.6m6.4m10.6m8.5m7.8m6.2m4.8m4.0m2.1m5.2m6.4m5.8m5.7m5.7m6.2m7.5m6.6m

PP&E

17.9k14.7k13.6k11.9k11.3k7.7k9.1k7.7k8.3k9.9k59.0k51.1k47.3k145.6k170.7k163.2k160.3k149.5k141.4k50.8k57.1k72.1k66.5k230.0k215.1k

Total Assets

10.2m8.0m6.8m5.9m7.5m7.4m5.3m10.3m10.5m13.4m13.3m11.1m10.3m8.6m7.2m6.3m4.2m7.2m8.4m7.5m7.4m7.3m6.5m7.8m6.8m

Accounts Payable

278.4k449.1k558.7k462.9k489.2k534.0k516.0k491.8k457.8k529.3k577.6k388.8k424.7k560.4k418.1k444.8k540.7k448.4k444.7k416.9k452.1k419.4k612.9k717.9k567.8k

Short-term debt

1.8m970.0k325.0k738.4k151.8k233.1k395.8k477.1k558.4k721.1k802.4k883.7k1.0m1.1m1.2m1.4m1.5m1.5m

Current Liabilities

2.9m2.1m2.1m1.8m3.4m3.3m3.1m11.5m10.7m8.4m1.7m688.7k711.7k1.2m706.9k531.6k3.7m3.7m2.9m1.1m1.3m1.1m1.3m1.6m1.4m

Long-term debt

407.7k1.8m259.8k1.5m1.6m1.8m

Total Debt

2.2m2.7m584.8k2.3m1.8m2.0m395.8k477.1k558.4k721.1k802.4k883.7k1.0m1.1m1.2m1.4m1.5m1.5m

Total Liabilities

13.2m5.0m4.1m4.3m5.1m4.6m4.6m8.0m3.7m2.9m

Common Stock

1.7m1.8m1.8m1.8m1.9m2.0m2.1m2.1m2.2m2.4m2.2m2.2m87.2k87.3k87.4k87.5k87.6k116.9k151.2k166.3k168.5k187.0k194.7k200.1k201.6k

Preferred Stock

350.0k350.0k14.0k14.0k14.0k14.0k

Additional Paid-in Capital

124.3m125.8m126.0m126.3m128.7m130.6m133.1m136.2m140.2m144.4m146.7m147.7m150.8m151.2m151.5m151.7m148.8m156.1m159.7m164.3m165.3m171.0m180.3m183.9m185.3m

Retained Earnings

(118.0m)(121.7m)(122.6m)(123.2m)(127.2m)(129.7m)(132.2m)(138.8m)(142.0m)(141.6m)(141.0m)(143.3m)(144.9m)(147.7m)(149.0m)(150.1m)(152.8m)(152.6m)(154.4m)(158.0m)(159.4m)(164.9m)(175.1m)(177.6m)(179.7m)

Total Equity

2.2m738.0k(339.0k)(893.1k)(1.3m)(1.4m)(3.2m)(5.7m)(4.8m)149.7k8.3m7.0m6.0m3.6m2.6m1.7m(3.8m)3.6m5.5m6.4m6.0m6.2m5.1m6.2m5.4m

Financial Leverage

4.5 x10.9 x-20 x-6.6 x-5.7 x-5.1 x-1.6 x-1.8 x-2.2 x89.5 x1.6 x1.6 x1.7 x2.4 x2.8 x3.7 x-1.1 x2 x1.5 x1.2 x1.2 x1.2 x1.3 x1.3 x1.3 x

Anixa Biosciences Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(7.4m)(4.3m)(10.1m)(9.6m)(1.4m)(5.0m)(5.0m)(14.2m)(11.8m)

Depreciation and Amortization

8.0k7.2k314.5k325.3k358.6k368.5k343.7k466.3k

Accounts Receivable

175.0k(225.0k)400.0k271.7k

Accounts Payable

10.3k174.7k641.3k(27.0k)(868.7k)88.0k107.1k101.7k3.8k

Cash From Operating Activities

(716.0k)(3.1m)(3.2m)(2.4m)1.4m(3.4m)(3.8m)(4.3m)(4.7m)

Purchases of PP&E

(9.0k)(1.6k)(54.8k)(146.5k)(30.2k)(38.4k)(175.5k)

Cash From Investing Activities

(2.1m)1.7m499.3k(2.5m)45.2k1.5m(2.7m)1.5m(525.5k)

Cash From Financing Activities

2.5m958.5k3.2m7.3m(400.6k)(2.7k)7.4m2.5m5.7m

Net Change in Cash

(320.1k)(434.3k)558.5k2.5m1.0m(1.9m)851.1k(283.5k)435.7k

Interest Paid

272.4k

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(4.6m)(886.1k)(1.8m)(2.4m)(2.1m)(4.6m)(7.2m)(3.6m)(6.9m)(6.5m)3.8m1.5m(86.6k)(1.6m)(2.9m)(4.0m)(1.6m)(1.4m)(3.2m)(1.9m)(3.3m)(8.9m)(5.0m)(7.5m)(9.7m)

Depreciation and Amortization

6.0k2.1k3.9k5.6k1.4k70.5k151.8k233.1k81.3k162.6k244.0k85.2k162.6k244.0k91.8k183.9k276.1k85.7k170.0k256.4k257.4k395.0k451.7k

Accounts Receivable

175.0k(653.4k)41.7k355.0k400.0k400.0k(221.0k)(490.0k)305.9k

Inventories

20.8k(2.1k)

Accounts Payable

(96.7k)150.2k238.3k132.3k436.1k508.9k572.2k(60.0k)(14.7k)28.1k152.2k(804.0k)(813.3k)655.5k132.0k150.9k201.2k161.3k437.3k(63.4k)(28.2k)(60.9k)30.9k135.9k(14.2k)

Cash From Operating Activities

(3.5k)(657.3k)(1.5m)(2.2m)(890.0k)(1.8m)(2.6m)(1.2m)(1.7m)(2.0m)4.7m2.9m2.2m(532.4k)(1.9m)(2.7m)(729.9k)(1.8m)(3.1m)(1.3m)(2.1m)(3.3m)(1.3m)(2.8m)(3.4m)

Purchases of PP&E

(9.0k)(850.0)(1.6k)(1.6k)(2.5k)(714.0)(1.8k)(54.8k)(54.8k)(54.8k)(106.0k)(141.1k)(144.6k)(14.1k)(14.1k)(16.9k)(2.5k)(11.8k)(31.9k)(175.5k)(175.5k)

Cash From Investing Activities

(2.9m)199.0k698.1k1.3m498.7k500.4k499.3k(2.4m)(2.1m)(2.6m)(204.8k)45.2k45.2k144.0k108.9k355.4k135.9k(1.5m)(3.5m)847.5k2.2m718.1k250.0k(925.5k)(275.5k)

Long-term Borrowings

(200.0k)

Cash From Financing Activities

2.3m147.3k208.5k208.5k1.8m2.2m2.8m3.5m3.5m7.3m(200.0k)(410.9k)18.2k23.4k(494.3k)3.7m5.9m677.4k1.8m2.2m4.5m5.0m

Net Change in Cash

(542.7k)(311.0k)(643.3k)(672.5k)1.4m934.1k642.3k(122.0k)(280.5k)2.8m4.4m2.7m1.8m(388.4k)(1.8m)(2.3m)(1.1m)388.6k(654.6k)(492.5k)833.1k(748.3k)1.1m766.4k1.3m

Anixa Biosciences Ratios

USDY, 2019

EV/EBIT

-5.8 x

EV/CFO

-14.7 x

Revenue/Employee

35.7k

Financial Leverage

1.3 x
View Anixa Biosciences profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more